Electrolyte disorders associated with the use of anticancer drugs

European Journal of Pharmacology

Volumn 777, Issue , 2016, Pages 78-87

  Liamis, George ^a   Filippatos, Theodosios D ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cyclophosphamide; Electrolytes; Mammalian targetofrapamycininhibitors; Platin; Tyrosine kinaseinhibitors; Vinca

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BLINATUMOMAB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN; ETARACIZUMAB; ICRUCUMAB; IFOSFAMIDE; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; STREPTOZOCIN; SURAMIN; TICILIMUMAB; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE; VOLOCIXIMAB; ZALUTUMUMAB;

AMINOACIDURIA; DRUG USE; ELECTROLYTE DISTURBANCE; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOURICEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR LYSIS SYNDROME; CHEMICALLY INDUCED; METABOLIC DISORDER; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; WATER-ELECTROLYTE IMBALANCE;

EID: 84959453758     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.02.064     Document Type: Review

References (184)

1. A. Abbas, M.M. Mirza, A.K. Ganti, and K. Tendulkar Renal toxicities of targeted therapies Target Oncol. 10 2015 487 499
2. G.K. Abou-Alfa, M. Capanu, E.M. O'Reilly, J. Ma, J.F. Chou, B. Gansukh, J. Shia, M. Kalin, S. Katz, L. Abad, D.L. Reidy-Lagunes, D.P. Kelsen, H.X. Chen, and L.B. Saltz A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma J. Hepatol. 60 2014 319 324
3. M. Adabala, K.D. Jhaveri, and M. Gitman Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient Nephrol. Dial. Transplant. 25 2010 3439 3442
4. J.M. Aitken, D.M. Hart, and D.A. Smith The effect of long-term mestranol administration on calcium and phosphorus homeostasis in oophorectomized women Clin. Sci. 41 1971 233 236
5. T. Al-Tweigeri, A.M. Magliocco, and J.F. DeCoteau Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature Gynecol. Oncol. 72 1999 120 122
6. I. Ali, W.A. Wani, K. Saleem, and A. Haque Platinum compounds: a hope for future cancer chemotherapy Anticancer Agents Med. Chem. 13 2013 296 306
7. H. Amlal, C.M. Krane, Q. Chen, and M. Soleimani Early polyuria and urinary concentrating defect in potassium deprivation Am. J. Physiol. Ren. Physiol. 279 2000 F655 F663
8. Y. Arakawa, M. Tamura, T. Sakuyama, K. Aiba, S. Eto, M. Yuda, Y. Tanaka, A. Matsumoto, and K. Nishikawa Early measurement of urinary N-acetyl-beta-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy J. Infect. Chemother. 21 2015 502 506
9. I. Arany, and R.L. Safirstein Cisplatin nephrotoxicity Semin. Nephrol. 23 2003 460 464
10. G. Ariaans, S. de Jong, J.A. Gietema, J.D. Lefrandt, E.G. de Vries, and M. Jalving Cancer-drug induced insulin resistance: innocent bystander or unusual suspect Cancer Treat. Rev. 41 2015 376 384
11. G. Ariceta, J. Rodriguez-Soriano, A. Vallo, and A. Navajas Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis Med. Pediatr. Oncol. 28 1997 35 40
12. A.J. Armstrong, T. Shen, S. Halabi, G. Kemeny, R.L. Bitting, P. Kartcheske, E. Embree, K. Morris, C. Winters, T. Jaffe, M. Fleming, and D.J. George A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer Clin. Genitourin. Cancer 11 2013 397 406
13. S.M. Arnold, J. Moon, S.K. Williamson, J.N. Atkins, S.H. Ou, M. LeBlanc, and S.G. Urba Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: southwest oncology group trial S0618 Investig. New Drugs 29 2011 352 359
14. J. Atsmon, and E. Dolev Drug-induced hypomagnesaemia: scope and management Drug Saf. 28 2005 763 788
15. G. Attard, A.H. Reid, R.J. Auchus, B.A. Hughes, A.M. Cassidy, E. Thompson, N.B. Oommen, E. Folkerd, M. Dowsett, W. Arlt, and J.S. de Bono Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer J. Clin. Endocrinol. Metab. 97 2012 507 516
16. Z.R. Barnard, B.P. Walcott, K.T. Kahle, B.V. Nahed, and J.V. Coumans Hyponatremia associated with Ipilimumab-induced hypophysitis Med. Oncol. 29 2012 374 377
17. H. Bashir, D. Crom, M. Metzger, J. Mulcahey, D. Jones, and M.M. Hudson Cisplatin-induced hypomagnesemia and cardiac dysrhythmia Pediatr. Blood Cancer 49 2007 867 869
18. K.M. Bell-McGuinn, C.M. Matthews, S.N. Ho, M. Barve, L. Gilbert, R.T. Penson, E. Lengyel, R. Palaparthy, K. Gilder, A. Vassos, W. McAuliffe, S. Weymer, J. Barton, and R.J. Schilder A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer Gynecol. Oncol. 121 2011 273 279
19. S.L. Bellin, and M. Selim Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature Gynecol. Oncol. 30 1988 104 113
20. T. Berghmans Hyponatremia related to medical anticancer treatment Support Care Cancer 4 1996 341 350
21. M.G. Bianchetti, C. Kanaka, A. Ridolfi-Luthy, A. Hirt, H.P. Wagner, and O.H. Oetliker Persisting renotubular sequelae after cisplatin in children and adolescents Am J. Nephrol. 11 1991 127 130
22. U. Bode, S.M. Seif, and A.S. Levine Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion Med. Pediatr. Oncol. 8 1980 295 303
23. H. Borghaei, C.J. Langer, M. Millenson, K.J. Ruth, S. Litwin, H. Tuttle, J.S. Seldomridge, M. Rovito, D. Mintzer, R. Cohen, and J. Treat Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung Cancer (NSCLC): results of OPN-017 J. Thorac. Oncol. 3 2008 1286 1292
24. R.B. Bressler, and D.P. Huston Water intoxication following moderate-dose intravenous cyclophosphamide Arch. Intern. Med. 145 1985 548 549
25. P.R. Brock, D.E. Koliouskas, T.M. Barratt, E. Yeomans, and J. Pritchard Partial reversibility of cisplatin nephrotoxicity in children J. Pediatr. 118 1991 531 534
26. K.R. Brown, and M.M. Leitao Jr. Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature Eur. J. Gynaecol. Oncol. 31 2010 107 108
27. J.J. Bruno, and T.W. Canada Possible pentostatin-induced symptomatic hyponatremia Pharmacotherapy 27 2007 164 169
28. L.W. Buie, J.J. Pecoraro, T.Z. Horvat, and R.J. Daley Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia Ann. Pharmacother. 49 2015 1057 1067
29. M. Buijs, D.K. Reyes, T.M. Pawlik, A.L. Blackford, R. Salem, W.A. Messersmith, C.D. Weekes, M. Mulcahy, I.R. Kamel, and J.F. Geschwind Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma Cancer 119 2013 1042 1049
30. Y. Chodakiewitz, S. Brown, J.L. Boxerman, J.M. Brody, and J.M. Rogg Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis Clin. Neurol. Neurosurg. 125 2014 125 130
31. K.Y. Chung, I. Gore, L. Fong, A. Venook, S.B. Beck, P. Dorazio, P.J. Criscitiello, D.I. Healey, B. Huang, J. Gomez-Navarro, and L.B. Saltz Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer J. Clin. Oncol. 28 2010 3485 3490
32. D.L. Citrin, P. Elson, M.S. Kies, and R. Lind Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implications Am J. Med. 76 1984 787 793
33. D.L. Citrin, C.B. Wallemark, R. Nadler, C. Geiger, K. Tuttle, E.H. Kaplan, and W. Hauck Estramustine affects bone mineral metabolism in metastatic prostate cancer Cancer 58 1986 2208 2213
34. C. Delbaldo, E. Raymond, K. Vera, L. Hammershaimb, K. Kaucic, S. Lozahic, M. Marty, and S. Faivre Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors Investig. New Drugs 26 2008 35 43
35. C. Diskin, L.M. Dansby, L. Radcliff, T.B. Carter, E. Graves, and A. Graves Recurrent hyponatremia after intrathecal methotrexate not related to antidiuretic hormone: is a natriuretic peptide activated? Am. J. Med. Sci. 331 2006 37 39
36. R. Dreicer, D. MacLean, A. Suri, W.M. Stadler, D. Shevrin, L. Hart, G.R. MacVicar, O. Hamid, J. Hainsworth, M.E. Gross, Y. Shi, I.J. Webb, and D.B. Agus Phase I/II trial of orteronel (TAK-700) - an investigational 17,20-lyase inhibitor - in patients with metastatic castration-resistant prostate cancer Clin. Cancer Res. 20 2014 1335 1344
37. M. Elisaf, M. Merkouropoulos, E.V. Tsianos, and K.C. Siamopoulos Pathogenetic mechanisms of hypomagnesemia in alcoholic patients J. Trace Elem. Med. Biol. 9 1995 210 214
38. M. Elisaf, H. Milionis, and K.C. Siamopoulos Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics Min. Electrol. Metab. 23 1997 105 112
39. L.J. Ettinger, P.S. Gaynon, M.D. Krailo, N. Ru, E.S. Baum, S.E. Siegel, and G.D. Hammond A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group Cancer 73 1994 1297 1301
40. F. Fakhouri, H. Guerraoui, C. Presne, J. Peltier, R. Delarue, P. Muret, and B. Knebelmann Thalidomide in patients with multiple myeloma and renal failure Br. J. Haematol. 125 2004 96 97
41. S. Faroqui, M. Levi, M. Soleimani, and H. Amlal Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia Kidney Int. 73 2008 1141 1150
42. T.D. Filippatos, and M.S. Elisaf Hyponatremia in patients with heart failure. world World J. Cardiol. 5 2013 317 328
43. T.D. Filippatos, E.N. Liberopoulos, N. Pavlidis, M.S. Elisaf, and D.P. Mikhailidis Effects of hormonal treatment on lipids in patients with cancer Cancer Treat. Rev. 35 2009 175 184
44. T.D. Filippatos, H.J. Milionis, and M.S. Elisaf Alterations in electrolyte equilibrium in patients with acute leukemia Eur. J. Haematol. 75 2005 449 460
45. B.J. Foster, K. Clagett-Carr, B. Leyland-Jones, and D. Hoth Results of NCI-sponsored phase I trials with carboplatin Cancer Treat. Rev. 12 Suppl A 1985 S43 S49
46. H. Frahm, and M. von Hulst Increased secretion of vasopressin and edema formation in high dosage methotrexate therapy Z. Gesamt. Inn. Med. 43 1988 411 414
47. H. Francois, P. Coppo, J.P. Hayman, B. Fouqueray, B. Mougenot, and P. Ronco Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss Am. J. Kidney Dis. 51 2008 298 301
48. C.G. Garofeanu, M. Weir, M.P. Rosas-Arellano, G. Henson, A.X. Garg, and W.F. Clark Causes of reversible nephrogenic diabetes insipidus: a systematic review Am. J. Kidney Dis. 45 2005 626 637
49. P.J. Gilbar, J. Richmond, J. Wood, and A. Sullivan Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide Ann. Pharmacother. 46 2012 e23
50. I.G. Glezerman Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis Ann. Oncol. 20 2009 1283 1285
51. I. Gravanis, A.S. Lopez, R.J. Hemmings, J.C. Jimenez, R. Garcia-Carbonero, I.G. Gallego, E.V. Gimenez, D. O'Connor, R. Giuliani, T. Salmonson, and F. Pignatti The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use Oncologist 18 2013 1032 1042
52. B. Greenbaum-Lefkoe, J.G. Rosenstock, J.B. Belasco, T.M. Rohrbaugh, and A.T. Meadows Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan Cancer 55 1985 44 46
53. G. Grignani, E. Palmerini, V. Ferraresi, L. D'Ambrosio, R. Bertulli, S.D. Asaftei, A. Tamburini, Y. Pignochino, D. Sangiolo, E. Marchesi, F. Capozzi, R. Biagini, M. Gambarotti, F. Fagioli, P.G. Casali, P. Picci, S. Ferrari, M. Aglietta, and G. Italian Sarcoma Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Lancet Oncol. 16 2015 98 107
54. W.M. Groenestege, S. Thebault, J. van der Wijst, D. van den Berg, R. Janssen, S. Tejpar, L.P. van den Heuvel, E. van Cutsem, J.G. Hoenderop, N.V. Knoers, and R.J. Bindels Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia J. Clin. Invest. 117 2007 2260 2267
55. J. Guo, Y. Huang, X. Zhang, F. Zhou, Y. Sun, S. Qin, Z. Ye, H. Wang, A. Jappe, P. Straub, N. Pirotta, and S. Gogov Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer 13 2013 136
56. H.T. Ha, J.S. Lee, S. Urba, R.J. Koenig, J. Sisson, T. Giordano, and F.P. Worden A phase II study of imatinib in patients with advanced anaplastic thyroid cancer Thyroid 20 2010 975 980
57. A.M. Hall, P. Bass, and R.J. Unwin Drug-induced renal Fanconi syndrome QJM 107 2014 261 269
58. T. Hamdi, S. Latta, B. Jallad, F. Kheir, M.N. Alhosaini, and A. Patel Cisplatin-induced renal salt wasting syndrome South Med. J. 103 2010 793 799
59. I.W. Hammond, J.A. Ferguson, K. Kwong, E. Muniz, and F. Delisle Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians? Pharmacoepidemiol. Drug. Saf. 11 2002 229 234
60. E. Harris, J. Behrens, D. Samson, A. Rahemtulla, N.H. Russell, and J.L. Byrne Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia Br. J. Haematol. 122 2003 160 161
61. J.R. Hecht, A. Cohn, S. Dakhil, M. Saleh, B. Piperdi, M. Cline-Burkhardt, Y. Tian, and W.Y. Go SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer Clin. Colorectal Cancer 14 2015 72 80
62. J. Hill, J. Shields, and V. Passero Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone J. Oncol. Pharm. Pract. 2015
63. K. Hoffmann, A. Marten, K. Lindel, S. Fritz, D. Jager, M.W. Buchler, and J. Schmidt Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature BMC Cancer 6 2006 128
64. S.C. Howard, S. Trifilio, T.K. Gregory, N. Baxter, and A. McBride Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review Ann. Hematol. 2016 Epub ahead of print
65. C.L. Huang, and E. Kuo Mechanism of hypokalemia in magnesium deficiency J. Am. Soc. Nephrol. 18 2007 2649 2652
66. F. Icli, H. Karaoguz, D. Dincol, A. Demirkazik, N. Gunel, R. Karaoguz, and A. Uner Severe vascular toxicity associated with cisplatin-based chemotherapy Cancer 72 1993 587 593
67. Y. Ito, Y. Arahata, Y. Goto, M. Hirayama, M. Nagamutsu, T. Yasuda, T. Yanagi, and G. Sobue Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome AJNR Am. J. Neuroradiol. 19 1998 415 417
68. H. Izzedine, V. Launay-Vacher, and G. Deray Thalidomide for the nephrologist Nephrol. Dial. Transplant. 20 2005 2011 2012
69. H. Izzedine, V. Launay-Vacher, C. Isnard-Bagnis, and G. Deray Drug-induced Fanconi syndrome Am. J. Kidney Dis. 41 2003 292 309
70. M.M. Javle, R.T. Shroff, H. Xiong, G.A. Varadhachary, D. Fogelman, S.A. Reddy, D. Davis, Y. Zhang, R.A. Wolff, and J.L. Abbruzzese Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies BMC Cancer 10 2010 368
71. P.J. Johnson, S. Qin, J.W. Park, R.T. Poon, J.L. Raoul, P.A. Philip, C.H. Hsu, T.H. Hu, J. Heo, J. Xu, L. Lu, Y. Chao, E. Boucher, K.H. Han, S.W. Paik, J. Robles-Avina, M. Kudo, L. Yan, A. Sobhonslidsuk, D. Komov, T. Decaens, W.Y. Tak, L.B. Jeng, D. Liu, R. Ezzeddine, I. Walters, and A.L. Cheng Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J. Clin. Oncol. 31 2013 3517 3524
72. D.P. Jones, and R.W. Chesney Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin Curr. Opin. Pediatr. 7 1995 208 213
73. A. Khanna Acquired nephrogenic diabetes insipidus Semin. Nephrol. 26 2006 244 248
74. Y. Kidera, H. Kawakami, T. Sakiyama, K. Okamoto, K. Tanaka, M. Takeda, H. Kaneda, S. Nishina, J. Tsurutani, K. Fujiwara, M. Nomura, Y. Yamazoe, Y. Chiba, S. Nishida, T. Tamura, and K. Nakagawa Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection PLoS One 9 2014 e101902
75. P.E. Kintzel Anticancer drug-induced kidney disorders Drug Saf. 24 2001 19 38
76. C. Kirch, B. Gachot, N. Germann, F. Blot, and G. Nitenberg Recurrent ifosfamide-induced hyponatraemia Eur. J. Cancer 33 1997 2438 2439
77. Y. Kobayashi, T. Yamauchi, H. Kiyoi, T. Sakura, T. Hata, K. Ando, A. Watabe, A. Harada, T. Taube, Y. Miyazaki, and T. Naoe Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia Cancer Sci. 106 2015 1590 1595
78. M. Koczywas, P.H. Frankel, T.W. Synold, H.J. Lenz, J.E. Mortimer, A.B. El-Khoueiry, D.R. Gandara, M.C. Cristea, V.M. Chung, D. Lim, K.L. Reckamp, D.H. Lau, L.A. Doyle, C. Ruel, M.I. Carroll, and E.M. Newman Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors Br. J. Cancer 111 2014 2268 2274
79. A.R. Kolarich, B.A. Reynolds, and C.D. Heldermon Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage Acta Oncol. 53 2014 1434 1436
80. J. Konner, R.J. Schilder, F.A. DeRosa, S.R. Gerst, W.P. Tew, P.J. Sabbatini, M.L. Hensley, D.R. Spriggs, and C.A. Aghajanian A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or Fallopian tube cancer Gynecol. Oncol. 110 2008 140 145
81. H. Lajer, and G. Daugaard Cisplatin and hypomagnesemia Cancer Treat. Rev. 25 1999 47 58
82. Lalami, Y., Garcia, C., Flamen, P., Ameye, L., Paesmans, M., Awada, A., 2014. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Head Neck.
83. M. Lam, and D.J. Adelstein Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin Am. J. Kidney Dis. 8 1986 164 169
84. N. Lameire Nephrotoxicity of recent anti-cancer agents Clin. Kidney J. 7 2014 11 22
85. T. Langer, W. Stohr, S. Bielack, M. Paulussen, J. Treuner, J.D. Beck, O. German Late Effects Working Group in the German Society of Pediatric, and Hematology Late effects surveillance system for sarcoma patients Pediatr. Blood Cancer 42 2004 373 379
86. V. Launay-Vacher, M. Aapro, G. De Castro, E. Cohen, G. Deray, M. Dooley, B. Humphreys, S. Lichtman, J. Rey, F. Scotté, H. Wildiers, and B. Sprangers Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN) Ann. Oncol. 26 2015 1677 1684
87. G. Laurent, V. Yernaux, D. Nonclercq, G. Toubeau, P. Maldague, P.M. Tulkens, and J.A. Heuson-Stiennon Tissue injury and proliferative response induced in rat kidney by CIS-diamminedichloroplatinum (II) Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 55 1988 129 145
88. K.J. Ledeganck, G.A. Boulet, J.J. Bogers, G.A. Verpooten, and B.Y. De Winter The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity PLoS One 8 2013 e57016
89. B.S. Lee, J.H. Lee, H.G. Kang, H. Hahn, J.H. Lee, H.Y. Shin, I.S. Ha, H.I. Cheong, H.S. Ahn, and Y. Choi Ifosfamide nephrotoxicity in pediatric cancer patients Pediatr. Nephrol. 16 2001 796 799
90. J.K. Lee, M. Capanu, E.M. O'Reilly, J. Ma, J.F. Chou, J. Shia, S.S. Katz, B. Gansukh, D. Reidy-Lagunes, N.H. Segal, K.H. Yu, K.Y. Chung, L.B. Saltz, and G.K. Abou-Alfa A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas Br. J. Cancer 109 2013 915 919
91. Y.C. Lee, J.S. Park, C.H. Lee, S.C. Bae, I.S. Kim, C.M. Kang, and G.H. Kim Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide Nephrol. Dial. Transplant. 25 2010 1520 1524
92. Y.K. Lee, and D.M. Shin Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer Korean J. Intern. Med. 7 1992 118 121
93. A.Y. Leem, H.S. Kim, B.W. Yoo, B.D. Kang, M.H. Kim, S.Y. Rha, and H.S. Kim Ifosfamide-induced Fanconi syndrome with diabetes insipidus Korean J. Intern. Med. 29 2014 246 249
94. G. Liamis, T.D. Filippatos, and M.S. Elisaf Treatment of hyponatremia: the role of lixivaptan Expert Rev. Clin. Pharm. 7 2014 431 441
95. G. Liamis, T.D. Filippatos, and M.S. Elisaf Correction of hypovolemia with crystalloid fluids: individualizing infusion therapy Postgrad. Med. 127 2015 405 412
96. G. Liamis, M. Kalogirou, V. Saugos, and M. Elisaf Therapeutic approach in patients with dysnatraemias Nephrol. Dial. Transplant. 21 2006 1564 1569
97. G. Liamis, E. Liberopoulos, G. Alexandridis, and M. Elisaf Hypomagnesemia in a department of internal medicine Magnes. Res. 25 2012 149 158
98. G. Liamis, H. Milionis, and M. Elisaf A review of drug-induced hyponatremia Am. J. Kidney Dis. 52 2008 144 153
99. G. Liamis, H.J. Milionis, and M. Elisaf A review of drug-induced hypernatraemia NDT Plus 2 2009 339 346
100. G. Liamis, H.J. Milionis, and M. Elisaf A review of drug-induced hypocalcemia J. Bone Miner. Metab. 27 2009 635 642
101. G. Liamis, H.J. Milionis, and M. Elisaf Medication-induced hypophosphatemia: a review QJM 103 2010 449 459
102. K. Liapis, J. Apostolidis, E. Charitaki, F. Panitsas, N. Harhalakis, and E. Nikiforakis Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib Ann. Pharmacother. 42 2008 1882 1886
103. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, C. Chang, Y.K. Kang, E. Assenat, H.Y. Lim, V. Boige, P. Mathurin, L. Fartoux, D.Y. Lin, J. Bruix, R.T. Poon, M. Sherman, J.F. Blanc, R.S. Finn, W.Y. Tak, Y. Chao, R. Ezzeddine, D. Liu, I. Walters, and J.W. Park Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J. Clin. Oncol. 31 2013 3509 3516
104. F. Locatelli, and F. Rossi Incidence and pathogenesis of tumor lysis syndrome Contrib. Nephrol. 147 2005 61 68
105. L.D. Locati, L. Licitra, L. Agate, S.H. Ou, A. Boucher, B. Jarzab, S. Qin, M.A. Kane, L.J. Wirth, C. Chen, S. Kim, A. Ingrosso, Y.K. Pithavala, P. Bycott, and E.E. Cohen Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments Cancer 120 2014 2694 2703
106. R. Loebstein, G. Atanackovic, R. Bishai, J. Wolpin, S. Khattak, G. Hashemi, M. Gobrial, S. Baruchel, S. Ito, and G. Koren Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children J. Clin. Pharmacol. 39 1999 454 461
107. P.M. LoRusso, S. Krishnamurthi, H. Youssoufian, N. Hall, F. Fox, A. Dontabhaktuni, D. Grebennik, and S. Remick Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a phase 1 study Investig. New Drugs 32 2014 303 311
108. J.P. Machiels, M. Peeters, C. Herremans, V. Surmont, P. Specenier, M. De Smet, K. Pilz, N. Strelkowa, D. Liu, and S. Rottey A phase I study of volasertib combined with afatinib, in advanced solid tumors Cancer Chemother. Pharmacol. 76 2015 843 851
109. D. Marples, J. Frokiaer, M.A. Knepper, and S. Nielsen Disordered water channel expression and distribution in acquired nephrogenic diabetes insipidus Proc. Assoc. Am. Physicians 110 1998 401 406
110. M. Martin, E. Diaz-Rubio, A. Casado, J.M. Lopez Vega, J. Sastre, and J. Almenarez Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial Am. J. Clin. Oncol. 15 1992 348 351
111. S. Marusic, N. Gojo-Tomic, V. Bacic-Vrca, and V. Bozikov Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera Eur. J. Clin. Pharmacol. 67 2011 757 758
112. M.B. May, and A. Glode Blinatumomab: a novel, bispecific, T-cell engaging antibody Am. J. Health Syst. Pharm. 73 2016 e6 e13
113. K.C. Micetich, B. Futscher, D. Koch, R.I. Fisher, and L.C. Erickson Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer J. Natl. Cancer Inst. 84 1992 256 260
114. N.C. Miltenburg, and W. Boogerd Chemotherapy-induced neuropathy: a comprehensive survey Cancer Treat. Rev. 40 2014 872 882
115. G. Miltiadous, D. Christidis, M. Kalogirou, and M. Elisaf Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients Eur. J. Intern. Med. 19 2008 1 7
116. G. Miltiadous, D.P. Mikhailidis, and M. Elisaf Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs J. Cardiovasc. Pharm. Ther. 8 2003 267 276
117. L. Min, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, J.J. Luke, H. Donahue, M. Davis, R.S. Carroll, and U.B. Kaiser Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study Clin. Cancer Res. 21 2015 749 755
118. L. Min, and N. Ibrahim Ipilimumab-induced autoimmune adrenalitis Lancet Diabetes Endocrinol. 1 2013 e15
119. M. Mohammadianpanah, S. Omidvari, A. Mosalaei, and N. Ahmadloo Cisplatin-induced hypokalemic paralysis Clin. Ther. 26 2004 1320 1323
120. Moore, D.C., Moore, A., Abiraterone-induced rhabdomyolysis: a case report. J. Oncol. Pharm. Pract., 2015, Epub ahead of print.
121. R.J. Morgan, T.W. Synold, J.A. Longmate, D.I. Quinn, D. Gandara, H.J. Lenz, C. Ruel, B. Xi, M.D. Lewis, A.D. Colevas, J. Doroshow, and E.M. Newman Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial Cancer Chemother. Pharmacol. 76 2015 897 907
122. B. Moriyama, S.A. Henning, J. Leung, O. Falade-Nwulia, P. Jarosinski, S.R. Penzak, and T.J. Walsh Adverse interactions between antifungal azoles and vincristine: review and analysis of cases Mycoses 55 2012 290 297
123. S. Muallem, and O.W. Moe When EGF is offside, magnesium is wasted J. Clin. Invest. 117 2007 2086 2089
124. T. Mune, K. Yasuda, M. Ishii, T. Matsunaga, and K. Miura Tetany due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma Intern. Med. 32 1993 434 437
125. S. O'Brien, D.A. Rizzieri, N. Vey, F. Ravandi, U.O. Krug, M.A. Sekeres, M. Dennis, A. Venditti, D.A. Berry, T.F. Jacobsen, K. Staudacher, T. Bergeland, and F.J. Giles Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia Br. J. Haematol. 158 2012 581 588
126. O. Oberlin, O. Fawaz, A. Rey, P. Niaudet, V. Ridola, D. Orbach, C. Bergeron, A.S. Defachelles, J.C. Gentet, C. Schmitt, H. Rubie, M. Munzer, D. Plantaz, A. Deville, V. Minard, N. Corradini, G. Leverger, and F. de Vathaire Long-term evaluation of Ifosfamide-related nephrotoxicity in children J. Clin. Oncol. 27 2009 5350 5355
127. Y. Ooka, T. Chiba, S. Ogasawara, K. Arai, E. Suzuki, A. Tawada, T. Yamashita, F. Kanai, S. Kaneko, and O. Yokosuka A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma Investig. New Drugs 32 2014 723 728
128. S. Osorio, A.G. Noblejas, A. Duran, and J.L. Steegmann Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response Am. J. Hematol. 82 2007 394 395
129. S. Owen, A. Hatfield, and L. Letvak Imatinib and altered bone and mineral metabolism N. Engl. J. Med. 355 2006 627
130. K. Panichpisal, F. Angulo-Pernett, S. Selhi, and K.M. Nugent Gitelman-like syndrome after cisplatin therapy: a case report and literature review BMC Nephrol. 7 2006 10
131. S.J. Park, J.H. Kim, and J.I. Shin Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide Nephrol. Dial. Transplant. 25 2010 3453
132. J.G. Penfield Multiple myeloma in end-stage renal disease Semin. Dial. 19 2006 329 334
133. M.A. Perazella, and H. Izzedine New drug toxicities in the onco-nephrology world Kidney Int. 87 2015 909 917
134. G. Perletti, E. Monti, E. Marras, A. Cleves, V. Magri, A. Trinchieri, and P.S. Rennie Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis Arch. Ital. Urol. Androl. 87 2015 121 129
135. C. Perrin, C. Fabre, J.L. Raoul, and E. Boucher Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment Acta Oncol. 45 2006 1135 1136
136. B.A. Peterson, A.J. Collins, N.J. Vogelzang, and C.D. Bloomfield 5-Azacytidine and renal tubular dysfunction Blood 57 1981 182 185
137. F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi, and S. Barni Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies Expert Opin. Drug. Saf. 11 Suppl 1 2012 S9 S19
138. H. Raftopoulos Diagnosis and management of hyponatremia in cancer patients Support. Care Cancer 15 2007 1341 1347
139. R.P. Rago, J.M. Miles, R.L. Sufit, D.R. Spriggs, and G. Wilding Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans Cancer 73 1994 1954 1959
140. T.S. Ravikumar, and T.B. Grage The syndrome of inappropriate ADH secretion secondary to vinblastine-bleomycin therapy J. Surg. Oncol. 24 1983 242 245
141. N.E. Ready, H.H. Pang, L. Gu, G.A. Otterson, S.P. Thomas, A.A. Miller, M. Baggstrom, G.A. Masters, S.L. Graziano, J. Crawford, J. Bogart, and E.E. Vokes Chemotherapy with or without maintenance Sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II Study-CALGB 30504 (Alliance) J. Clin. Oncol. 33 2015 1660 1665
142. A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F.S. Hodi, J. Schachter, A.C. Pavlick, K.D. Lewis, L.D. Cranmer, C.U. Blank, S.J. O'Day, P.A. Ascierto, A.K. Salama, K.A. Margolin, C. Loquai, T.K. Eigentler, T.C. Gangadhar, M.S. Carlino, S.S. Agarwala, S.J. Moschos, J.A. Sosman, S.M. Goldinger, R. Shapira-Frommer, R. Gonzalez, J.M. Kirkwood, J.D. Wolchok, A. Eggermont, X.N. Li, W. Zhou, A.M. Zernhelt, J. Lis, S. Ebbinghaus, S.P. Kang, and A. Daud Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Lancet Oncol. 16 2015 908 918
143. P.S. Ritch CIS-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone Cancer 61 1988 448 450
144. G.L. Robertson, N. Bhoopalam, and L.J. Zelkowitz Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone Arch. Intern. Med. 132 1973 717 720
145. J. Rodriguez-Pascual, E. Cheng, P. Maroto, and I. Duran Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma Anticancer Drugs 21 2010 478 486
146. R. Rossi, J. Pleyer, P. Schafers, N. Kuhn, R. Kleta, T. Deufel, and H. Jurgens Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients Med. Pediatr. Oncol. 32 1999 177 182
147. H. Rubin Central roles of Mg2+ and MgATP2- in the regulation of protein synthesis and cell proliferation: significance for neoplastic transformation Adv. Cancer Res. 93 2005 1 58
148. H. Rubin The logic of the Membrane, Magnesium, Mitosis (MMM) model for the regulation of animal cell proliferation Arch. Biochem. Biophys. 458 2007 16 23
149. V. Sahni, D. Choudhury, and Z. Ahmed Chemotherapy-associated renal dysfunction Nat. Rev. Nephrol. 5 2009 450 462
150. V. Saloura, E.E. Cohen, L. Licitra, S. Billan, J. Dinis, S. Lisby, and T.C. Gauler An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck Cancer Chemother. Pharmacol. 73 2014 1227 1239
151. A.I. Sanchez-Fructuoso, J.M. Santin Cantero, I. Perez Flores, R. Valero San Cecilio, N. Calvo Romero, and R. Vilalta Casas Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen Transplant. Proc. 42 2010 3047 3049
152. D. Santini, S. Galluzzo, B. Vincenzi, A. Zoccoli, E. Ferraro, C. Lippi, V. Altomare, G. Tonini, and F. Bertoldo Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients Ann. Oncol. 21 2010 185 186
153. J.H. Schiller, T. Larson, S.H. Ou, S. Limentani, A. Sandler, E. Vokes, S. Kim, K. Liau, P. Bycott, A.J. Olszanski, and J. von Pawel Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J. Clin. Oncol. 27 2009 3836 3841
154. R.L. Schilsky, A. Barlock, and R.F. Ozols Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer Cancer Treat. Rep. 66 1982 1767 1769
155. D. Schrag, K.Y. Chung, C. Flombaum, and L. Saltz Cetuximab therapy and symptomatic hypomagnesemia J. Natl. Cancer Inst. 97 2005 1221 1224
156. R. Shameem, M.S. Hamid, K.Y. Xu, and S. Wu Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate Cancer World J. Clin. Oncol. 6 2015 64 72
157. A.T. Shaw, and J.A. Engelman Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 370 2014 2537 2539
158. T. Shimizu, I. Okamoto, K. Tamura, T. Satoh, M. Miyazaki, Y. Akashi, T. Ozaki, M. Fukuoka, and K. Nakagawa Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors Cancer Chemother. Pharmacol. 65 2010 243 250
159. T. Shukuya, T. Yamanaka, T. Seto, H. Daga, K. Goto, H. Saka, S. Sugawara, T. Takahashi, S. Yokota, H. Kaneda, T. Kawaguchi, S. Nagase, T. Oguri, Y. Iwamoto, T. Nishimura, Y. Hattori, K. Nakagawa, Y. Nakanishi, N. Yamamoto, and G. West Japan Oncology Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial Lancet Oncol. 16 2015 1630 1638
160. L.L. Siu, and M.J. Moore Use of mesna to prevent ifosfamide-induced urotoxicity Support Care Cancer 6 1998 144 154
161. R. Skinner Chronic ifosfamide nephrotoxicity in children Med. Pediatr. Oncol. 41 2003 190 197
162. + homeostasis Semin. Nephrol. 7 1987 253 262
163. D.R. Spigel, J.D. Hainsworth, C.M. Lane, B. Clark, H.A. Burris, and F.A. Greco Phase II trial of vinflunine in relapsed small cell lung cancer J. Thorac. Oncol. 5 2010 874 878
164. A.F. Stewart, T. Keating, and P.E. Schwartz Magnesium homeostasis following chemotherapy with cisplatin: a prospective study Am. J. Obstet. Gynecol. 153 1985 660 665
165. W. Stohr, M. Paulides, S. Bielack, H. Jurgens, E. Koscielniak, R. Rossi, T. Langer, and J.D. Beck Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system Pediatr. Blood Cancer 48 2007 140 147
166. W. Stohr, M. Paulides, S. Bielack, H. Jurgens, J. Treuner, R. Rossi, T. Langer, and J.D. Beck Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System Pediatr. Blood Cancer 48 2007 447 452
167. V. Stojanovska, S. Sakkal, and K. Nurgali Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity Am. J. Physiol. Gastrointest. Liver Physiol. 308 2015 G223 G232
168. T. Tanvetyanon, and P.J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann. Oncol. 17 2006 897 907
169. B.A. Teply, and E.J. Lipson Identification and management of toxicities from immune checkpoint-blocking drugs Oncology 28 Suppl 3 2014 S30 S38
170. B. Terrier, D. Joly, D. Ghez, B. Knebelmann, F. Fakhouri, and A. Hummel Reversible paraparesis in multiple myeloma with renal failure Nephrol. Dial. Transplant. 21 2006 1439 1440
171. P.C. Thuss-Patience, U. Peters, K. Jurkat-Rott, D. Pink, A. Kretzschmar, B. Dorken, and P. Reichardt Acute hypokalemic tetraparesis induced by intravenous methotrexate J. Clin. Oncol. 21 2003 1896 1897
172. D.L. Trump, and L. Hortvet Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms Cancer Treat. Rep. 69 1985 259 261
173. Y. Tsutsumi, S. Shiratori, A. Nakata, T. Kawamura, S. Mashiko, M. Ibata, A. Mori, J. Tanaka, M. Asaka, M. Imamura, and N. Masauzi Hyponatremia after administration of conditioning regimen in myelodysplastic syndrome with empty sella after glandula pituitaria surgery Ann. Hematol. 86 2007 843 844
174. S.L. Vanhees, R. Paridaens, and J.F. Vansteenkiste Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review Ann. Oncol. 11 2000 1061 1065
175. N. Vantard, F. Ranchon, V. Schwiertz, C. Gourc, N. Gauthier, M.G. Guedat, S. He, E. Kiouris, C. Alloux, B. You, P.J. Souquet, G. Freyer, G. Salles, V. Trillet-Lenoir, and C. Rioufol EPICC study: evaluation of pharmaceutical intervention in cancer care J. Clin. Pharm. Ther. 40 2015 196 203
176. A.E. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology Toxicol. Pathol. 32 2004 577 590
177. M.M. Vickers, C.S. Karapetis, D. Tu, C.J. O'Callaghan, T.J. Price, N.C. Tebbutt, G. Van Hazel, J.D. Shapiro, N. Pavlakis, P. Gibbs, J. Blondal, U. Lee, J.M. Meharchand, R.L. Burkes, S.H. Rubin, J. Simes, J.R. Zalcberg, M.J. Moore, L. Zhu, and D.J. Jonker Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG Co.17 Ann. Oncol. 24 2013 953 960
178. B. Vincenzi, D. Santini, S. Galluzzo, A. Russo, F. Fulfaro, M. Silletta, F. Battistoni, L. Rocci, B.B. Zobel, V. Adamo, G. Dicuonzo, and G. Tonini Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome Clin. Cancer Res. 14 2008 4219 4224
179. J. Vuky, H.T. Pham, S. Warren, E. Douglass, K. Badiozamani, B. Madsen, A. Hsi, and G. Song Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 82 2012 e609 e615
180. Q. Wang, Y. Qi, D. Zhang, C. Gong, A. Yao, Y. Xiao, J. Yang, F. Zhou, and Y. Zhou Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials Tumour Biol. 36 2015 3471 3482
181. X. Wu, U. Ackermann, and H. Sonnenberg Potassium depletion and salt-sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions Clin. Exp. Hypertens. 17 1995 989 1008
182. Y. Yamada, K. Higuchi, K. Nishikawa, M. Gotoh, N. Fuse, N. Sugimoto, T. Nishina, K. Amagai, K. Chin, Y. Niwa, A. Tsuji, H. Imamura, M. Tsuda, H. Yasui, H. Fujii, K. Yamaguchi, H. Yasui, S. Hironaka, K. Shimada, H. Miwa, C. Hamada, and I. Hyodo Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer Ann. Oncol. 26 2015 141 148
183. W. Yeo, S.L. Chan, F.K. Mo, C.M. Chu, J.W. Hui, J.H. Tong, A.W. Chan, J. Koh, E.P. Hui, H. Loong, K. Lee, L. Li, B. Ma, K.F. To, and S.C. Yu Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC) - a correlative study to explore potential biomarkers for response BMC Cancer 15 2015 395
184. A.X. Zhu, T.A. Abrams, R. Miksad, L.S. Blaszkowsky, J.A. Meyerhardt, H. Zheng, A. Muzikansky, J.W. Clark, E.L. Kwak, D. Schrag, K.R. Jors, C.S. Fuchs, A.J. Iafrate, D.R. Borger, and D.P. Ryan Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102